Why Gilead Sciences (GILD) Stock Is Down Today

Updated from 11:13 a.m. with closing price.

NEW YORK (TheStreet) -- Shares of Gilead Sciences  (GILD) fell -1.4% to $105.36 at the closing bell on Friday after Bloomberg reported the company is close to a deal with generic drugmakers to bring cheaper versions of its $84,000 hepatitis C drug Sovaldi to approximately 80 developing nations, including India, Pakistan and Indonesia.

See why one investment manager says fears about lower emerging market pricing for Gilead's hepatitis drug are overblown:


WATCH: More market update videos on TheStreet TV

The licensing deal could go into effect as soon as the middle of this month. It would permit the generic drugmakers to manufacture Sovaldi and another experimental pill that combines Sovaldi with another Gilead hepatitis drug, executive vice president Gregg Alton told Bloomberg.

Gilead intends to sell Sovaldi directly in certain lower income countries, including India, at $900 for 12 weeks of therapy. Sovaldi sells in the U.S. for the controversial price of $1,000 apiece, or $84,000 for 12 weeks. Patients who take Sovaldi stay on it for either 12 weeks or 24 weeks.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More than 34.2 million shares changed hands Friday, compared to the average volume of 12,293,000. The stock hit an intraday low of $97.55.

Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a "buy" with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

If you liked this article you might like

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer